Potemin, Sergey
Kübler, Jens
Uvarov, Ivan
Wenz, Frederik
Giordano, Frank http://orcid.org/0000-0001-5243-4781
Article History
Received: 11 December 2018
Accepted: 5 January 2020
First Online: 10 January 2020
Ethics approval and consent to participate
: This retrospective analysis was approved by the Institutional Review Board.
: Not applicable.
: FW is an advisor, consultant and/or speaker for Celgene GmbH, Roche Pharma AG, Eli Lilly and Company, Ipsen Pharma GmbH, receives travel and research grants from Carl Zeiss Meditec AG and Elekta AB, is on the Carl Zeiss Meditec AG speaker’s bureau and holds patents related with Carl Zeiss Meditec AG. FG is an advisor, consultant and/or speaker for Carl Zeiss Meditec AG, NOXXON Pharma AG, MSD Sharp and Dohme, Roche Pharma AG and holds patents related with Carl Zeiss Meditec AG. All other authors declare no conflict of interest.